Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase-Ⅰ/Ⅱa-Studie von HMPL-A251 bei Teilnehmern mit fortgeschrittenen oder metastasierten HER2-exprimierenden soliden Tumoren

17. September 2026 aktualisiert von: Hutchmed

Eine Phase-Ⅰ/Ⅱa-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Immunogenität und vorläufigen Wirksamkeit von HMPL-A251 bei Teilnehmern mit fortgeschrittenen oder metastasierten HER2-exprimierenden soliden Tumoren

This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.

Studienübersicht

Status

Rekrutierung

Detaillierte Beschreibung

  • To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
  • To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors

Studientyp

Interventionell

Einschreibung (Geschätzt)

147

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Beijing, China
        • Rekrutierung
        • Peking University First Hospital
        • Kontakt:
        • Kontakt:
          • Yu Fan
      • Changsha, China
        • Rekrutierung
        • Hunan Cancer Hospital
        • Kontakt:
      • Guangzhou, China
        • Rekrutierung
        • Sun Yat-sen University Cancer Center
        • Kontakt:
      • Hefei, China
        • Rekrutierung
        • The First Affiliated Hospital of Anhui Medical University
        • Kontakt:
      • Shanghai, China
        • Rekrutierung
        • Fudan University Shanghai Cancer Center
        • Kontakt:
          • Jian Zhang
        • Kontakt:
      • Shenyang, China
        • Rekrutierung
        • The First Hospital of China Medical University
        • Kontakt:
      • Zhengzhou, China
        • Rekrutierung
        • Henan Cancer Hospital
        • Kontakt:
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Rekrutierung
        • SCRI HealthONE
        • Kontakt:
    • Florida
      • Plantation, Florida, Vereinigte Staaten, 33322
      • Plantation, Florida, Vereinigte Staaten, 33322
        • Rekrutierung
        • Florida Clinical Trials Group LLC (Plantation)
        • Kontakt:
      • Tamarac, Florida, Vereinigte Staaten, 33321
        • Noch keine Rekrutierung
        • Florida Clinical Trials Group LLC (Tamarac)
        • Kontakt:
          • Chintan Ghandi
    • New Jersey
      • East Brunswick, New Jersey, Vereinigte Staaten, 08816
        • Noch keine Rekrutierung
        • START New Jersey
        • Kontakt:
          • Bruno Fang
    • New York
      • New York, New York, Vereinigte Staaten, 10065
        • Noch keine Rekrutierung
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
          • Vicky Makker
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Rekrutierung
        • Cleveland Clinic Taussig Cancer Center
        • Kontakt:
    • Washington
      • Tacoma, Washington, Vereinigte Staaten, 98405
        • Noch keine Rekrutierung
        • Northwest Medical Specialties, PLLC
        • Kontakt:
          • Jorge Chaves

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Histologically confirmed unresectable advanced or metastatic disease.
  2. Have at least one measurable lesion per RECIST v1.1;
  3. Life expectancy ≥ 12 weeks;
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
  5. Weight ≥ 35 kg;

Exclusion Criteria:

  1. An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
  2. Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
  3. Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
  4. Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
  5. Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
  6. Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part A(Phase I)

Dose Escalation

Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Experimental: Part B(Phase IIa)

Dose Expansion/Dose Optimization

Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum Tolerated Dose (MTD)
Zeitfenster: Approximately 12 months

At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251

Approximately 12 months
Recommended doses for expansion (RDE)
Zeitfenster: Approximately 12 months

The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data.

Approximately 12 months
Overview of Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Approximately 24 months

All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA).

Approximately 24 months
Objective Response Rate (ORR)
Zeitfenster: At least 6 weeks post dose of first participant up to approximately 24 months

ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1.

At least 6 weeks post dose of first participant up to approximately 24 months
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Zeitfenster: Approximately 12 months

The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.

Approximately 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease control rate (DCR)
Zeitfenster: Approximately 2 years

The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks.

Approximately 2 years
Duration of response (DoR)
Zeitfenster: Approximately 2 years

Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause.

Approximately 2 years
Time to response (TTR)
Zeitfenster: Approximately 2 years

Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR)

Approximately 2 years
Progression-free survival (PFS)
Zeitfenster: Approximately 2 years

The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first.

Approximately 2 years
Overall survival (OS)
Zeitfenster: Approximately 2 years

Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first.

Approximately 2 years
Maximum plasma/serum concentration (Cmax)
Zeitfenster: Cycle 1 and Cycle 3 (21-day cycle)

Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3.

Cycle 1 and Cycle 3 (21-day cycle)
Time to maximum plasma/serum concentration (Tmax)
Zeitfenster: Cycle 1 and Cycle 3 (21-day cycle)

Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609

Cycle 1 and Cycle 3 (21-day cycle)
Area under the plasma/serum concentration-time curve (AUC)
Zeitfenster: Cycle 1 and Cycle 3 (21-day cycle)

Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis

Cycle 1 and Cycle 3 (21-day cycle)
Pre-dose plasma/serum concentration (Cmin)
Zeitfenster: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months

Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609.

Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
Immunogenicity of HMPL-A251
Zeitfenster: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months

Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251

Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

16. Dezember 2025

Primärer Abschluss (Geschätzt)

30. November 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

11. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2025

Zuerst gepostet (Tatsächlich)

14. November 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2025-251-GLOB1

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren